<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">LOMEFLOXACIN</span><br/>(lo-me-flox'a-cin)<br/><span class="topboxtradename">Maxaquin<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">quinolone antibiotic</span><br/><b>Prototype: </b>Ciprofloxacin<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>400 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>An oral fluoroquinolone broad spectrum bactericidal agent that inhibits DNA gyrase, an enzyme necessary for bacterial DNA
         replication and some aspects of its transcription, repair, recombination, and transposition.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits replication of susceptible gram-negative and gram-positive bacteria. Antibiotic spectrum of activity is similar to
         that of other fluoroquinolones.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Urinary tract infections, transurethral surgery prophylaxis.</p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Lower respiratory tract infections.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to lomefloxacin or any other quinolone, lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Kidney disease; patients with a history of epilepsy, psychosis, or increased intracranial pressure; pregnancy (category C);
         children and adolescents.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Urinary Tract &amp; Lower Respiratory Tract Infections</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg q.d. times 10 d<br/><br/><span class="indicationtitle">Transurethral Surgery Prophylaxis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 400 mg 26 h before surgery<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Avoid giving mineral supplements or vitamins with iron or zinc within 2 h of lomefloxacin.</li>
<li>Do not give antacids with magnesium, aluminum, or sucralfate within 4 h before or 2 h after drug.</li>
<li>Give hemodialysis patients an initial 400 mg loading dose followed by a 200 mg/d maintenance dose.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CNS:</span>
<span class="speceff-common">Headache, peripheral neuropathy</span>. <span class="typehead">GI:</span> Nausea, abdominal discomfort. <span class="typehead">Skin:</span> Photosensitivity. <span class="typehead">Musculoskeletal:</span> Risk of tendon rupture (rare). 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>May cause false positive on <span class="alt">opiate screening tests.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead"> Drug:</span>
<span class="classification"> aluminum-</span> and <span class="classification">magnesium-containing antacids</span> decrease systemic bioavailability of lomefloxacin. Concurrent <span class="classification">corticosteroid</span> use may increase the risk of tendon rupture. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Distribution:</span> Crosses placenta; distributed into breast milk. <span class="typehead">Elimination:</span> 76% excreted in urine within 48 h. <span class="typehead">Half-Life:</span> 6.357.77 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Draw C&amp;S prior to first dose; drug may be started pending results of C&amp;S.</li>
<li>Take thorough history of hypersensitivity reactions to quinolones or other drugs prior to therapy.</li>
<li>Discontinue lomefloxacin and notify physician at the first sign of a skin rash or other allergic reaction.</li>
<li>Monitor for seizures, especially in patients with known or suspected CNS disorders. Discontinue lomefloxacin and notify physician
            immediately if a seizure occurs.
         </li>
<li>Assess for S&amp;S of superinfection (see Appendix F).</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Notify physician of loose stools or diarrhea promptly.</li>
<li>Drink fluids liberally, if not contraindicated.</li>
<li>Take appropriate cautions, dizziness or light-headedness may occur.</li>
<li>Be aware of the possibility of phototoxicity; avoid excessive sunlight or artificial ultraviolet light.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>